Roberto Verlato

Roberto Verlato

Auto-generated profile, based on publicly available information

Roberto Verlato

Cardiologia Camposampiero – AULSS6 Euganea, Italy (E. Bertaglia, R.V., F.R.).

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2020 in Circulation: Arrhythmia and Electrophysiology
Verified
Journal Article
Closed access
PDF file
FMFederico Migliore
Federico Migliore
Alessandro ZorziAlessandro Zorzi
Alessandro Zorzi
Dario GregoriDario Gregori
Dario Gregori
AMAlvise Del Monte
Alvise Del Monte
PFPasquale Valerio Falzone
Pasquale Valerio Falzone
SISabino Iliceto
Sabino Iliceto

28 December 2020 in Pacing and Clinical Electrophysiology
Verified
Journal Article
Closed access
PDF file
DMDaniele Malaspina
Daniele Malaspina
FBFrancesco Brasca
Francesco Brasca
Saverio IacopinoSaverio Iacopino
Saverio Iacopino
GAGiuseppe Arena
Giuseppe Arena
GMGiulio Molon
Giulio Molon
GPGiovanni Battista Perego
Giovanni Battista Perego

2 May 2022 in Pacing and Clinical Electrophysiology
Verified
Journal Article
Closed access
MMMassimiliano Manfrin
Massimiliano Manfrin
RVRoberto Verlato
Roberto Verlato
GAGiuseppe Arena
Giuseppe Arena
PPPaolo Pieragnoli
Paolo Pieragnoli
GMGiulio Molon
Giulio Molon
Saverio IacopinoSaverio Iacopino
Saverio Iacopino

15 February 2007 in EP Europace
Verified
Journal Article
Open access
PDF file
EBEmanuele Bertaglia
Emanuele Bertaglia
GSGiuseppe Stabile
Giuseppe Stabile
GSGaetano Senatore
Gaetano Senatore
ACAndrea Colella
Andrea Colella
MGMaurizio Del Greco
Maurizio Del Greco
RVRoberto Verlato
Roberto Verlato
Aims Catheter Ablation for the Cure of Atrial Fibrillation 2 study is a prospective, randomized trial aimed to demonstrate the efficacy of catheter ablation with combined lesions in the right and left atria, in preventing atrial fibrillation (AF) recurrences among patients with recurrent persistent AF refractory to one antiarrhythmic drug, in comparison with the best pharmacological therapy. Methods and results Enrolment is limited to patients aged between 18 and 70 years who have experienced at least one documented relapse of persistent AF during antiarrhythmic drug therapy. One hundred and twenty-six patients will be randomized to ablation or antiarrhythmic drug therapy in a 2 : 1 manner. In the ablation group, the patients will undergo right and left atrial linear ablation. Control group patients will be treated with the best antiarrhythmic drug. After an initial blanking period of 2 months patients will be followed for 24 months. Primary endpoint of the study is the absence of documented persistent atrial tachyarrhythmias relapse during the first 24 months after the blanking period. Enrolment is scheduled in 14 centres in Italy, UK, Austria, and Finland. Seventy-two patients have currently been enrolled. Conclusion This study will provide important data about the efficacy of catheter ablation in comparison with antiarrhythmic drugs for the treatment of persistent AF.

8 June 2020 in Pacing and Clinical Electrophysiology
Verified
Journal Article
Closed access
PDF file
RVRoberto Verlato
Roberto Verlato
PPPaolo Pieragnoli
Paolo Pieragnoli
SISaverio Iacopino
Saverio Iacopino
WRWerner Rauhe
Werner Rauhe
GMGiulio Molon
Giulio Molon
CTClaudio Tondo
Claudio Tondo

1 August 2025 in Circulation: Arrhythmia and Electrophysiology
Verified
Journal Article
Closed access
SMSchiavone Marco
Schiavone Marco
GMGiulio Molon
Giulio Molon
PPPaolo Pieragnoli
Paolo Pieragnoli
Giuseppe ArenaGiuseppe Arena
Giuseppe Arena
Saverio IacopinoSaverio Iacopino
Saverio Iacopino
CTClaudio Tondo
Claudio Tondo
BACKGROUND: Cryoballoon pulmonary vein isolation has become an established treatment for atrial fibrillation (AF). However, data on long-term outcomes beyond 5 years are scarce. This prospective analysis aimed to evaluate the long-term outcome after cryoballoon pulmonary vein isolation. METHODS: Data from consecutive patients treated with cryoballoon pulmonary vein isolation for symptomatic AF between 2012 and 2018 in 13 institutions were analyzed. Patients with ≥5-year follow-up after the index procedure were included. Arrhythmia recurrence was defined as AF or atrial tachycardia lasting >30 seconds beyond a 3-month blanking period. RESULTS: A total of 1330 patients were enrolled (28.4% female patients, mean age was 60.1±10.5 years). Patients with paroxysmal AF accounted for 73.1%; the median history of AF was 36.0 (13.0–75.0) months. The rate of AF/atrial tachycardia recurrences progressively increased over time (event rate: 52.5% [49.4%–55.8%] at 8-year follow-up). A low incidence of progression to permanent AF was seen in the entire cohort (7.0%). Importantly, 15.7% of patients underwent a redo ablation for AF during follow-up; in 45.9% of these cases, all PVs were isolated at the redo procedure, with a median number of PVs isolated after the index procedure being 3 (1–4) veins. Independent predictors of arrhythmia recurrences were AF type (persistent AF: hazard ratio, 1.36 [95% CI, 1.14–1.62]; P <0.001) and chronic kidney disease (hazard ratio, 1.77 [95% CI, 1.12–2.81]; P =0.016) in multivariate analysis. CONCLUSIONS: Cryoballoon pulmonary vein isolation as the index procedure for AF ablation resulted in a favorable long-term outcome in patients with symptomatic AF, with limited progression towards permanent AF during follow-up. Persistent AF was the strongest predictor of recurrences at long-term follow-up.